TDC
AEMD icon

Thompson Davis & Co’s Aethlon Medical AEMD Stock Holding History

Thompson Davis & Co’s Portfolio AEMD Stock Details AEMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13
Closed -$11K – 90
2022
Q2 		$11K Buy
+13
New +$12.1K 0.02% 93
2016
Q2 		– Hold
0
– -$16K – 1047
2016
Q1 		– Hold
0
– – – 518

Other funds holding AEMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Davis & Co's AEMD Position: Q3 2022 in Review

Thompson Davis & Co sold out of Aethlon Medical (AEMD) in Q3 2022, closing a stake of 13 shares — an estimated $11K sold.

Thompson Davis & Co first reported a position in AEMD in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 25 funds tracked by Wall St. Rank hold AEMD as of Q3 2022.

  • Thompson Davis & Co reported no remaining Aethlon Medical position as of Q3 2022 after selling out during the quarter.
  • Thompson Davis & Co sold 13 Aethlon Medical shares in Q3 2022, an estimated $11K.
  • Thompson Davis & Co first reported a position in Aethlon Medical in Q2 2022 and held it in 1 quarter.
  • Thompson Davis & Co's Aethlon Medical position peaked at $11K in Q2 2022.
  • 25 funds tracked by Wall St. Rank held Aethlon Medical as of Q3 2022.

Based on Thompson Davis & Co's 13F filing for Q3 2022, filed 9 Nov 2022.